The Efficacy of Adjuvant Capecitabine-Containing Regimens in Medium- to High-Risk Breast Cancer


The Efficacy of Adjuvant Capecitabine-Containing Regimens in Medium- to High-Risk Breast Cancer
Slides from presentations at SABCS 2010 and transcribed comments from a recent interview with William J Gradishar, MD (1/4/11)

O’Shaughnessy J et al. First efficacy results of a randomized, open-label, phase III study of adjuvant doxorubicin plus cyclophosphamide, followed by docetaxel with or without capecitabine, in high-risk early breast cancer. San Antonio Breast Cancer Symposium 2010;Abstract S4-2.

Joensuu H et al. FinXX final 5-year analysis: Results of the randomized, open-label, phase III trial in medium-to-high risk early breast cancer. San Antonio Breast Cancer Symposium 2010;Abstract S4-1.

Dr Gradishar is Director of Breast Medical Oncology at the Robert H Lurie Comprehensive Cancer Center and Professor of Medicine at the Northwestern University Feinberg School of Medicine in Chicago, Illinois.